Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-FODMAP Diet for Gastrointestinal Symptoms in Endometriosis: A Systematic Review.

Nutrients·2026
Same author

The Impact of Staging Investigations in HER2-Low, Low-Risk Patients.

Breast care (Basel, Switzerland)·2026
Same author

Assessment of breast cancer and feasibility of subtyping of breast cancer using thoracoabdominal staging photon-counting detector computed tomography.

Scientific reports·2026
Same author

Real-World Assessment of Prophylactic Anakinra on Neurotoxicity and Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory B-Cell Lymphoma: An Inverse Probability of Treatment Weighting Analysis.

Transplantation and cellular therapy·2026
Same author

Prognostic Impact of UBA1 Expression in Breast Cancer.

Journal of Cancer·2026
Same author

Is re-irradiation combined with chemotherapy an option for inoperable local recurrence of previously irradiated breast cancer? A collection of cases.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Related Experiment Video

Updated: Jun 26, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Real-World Data Analysis of CDK4/6 Inhibitor Therapy-A Patient-Centric Single Center Study.

Isabell Ge1,2,3,4, Kai Berner3,4,5, Marlene Mathis3,4

  • 1Department of Gynecology and Obstetrics, University Hospital Basel, 4031 Basel, Switzerland.

Cancers
|May 11, 2024
PubMed
Summary

Real-world CDK4/6 inhibitors (CDKis) show varied breast cancer efficacy. Progesterone receptor status, metastatic sites, and treatment adjustments significantly impact outcomes, guiding personalized strategies.

Keywords:
CDK4/6 inhibitorsadverse eventsbreast cancermetastasismultivariate analysispersonalized treatmentpredictionprogesterone receptor (PR)progression-free survival (PFS)therapeutic benefittime-to-treatment failure (TTF)

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.8K

Related Experiment Videos

Last Updated: Jun 26, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.8K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Real-world effectiveness of CDK4/6 inhibitors (CDKis) in breast cancer is under investigation due to significant patient response variability.
  • Understanding factors influencing treatment outcomes is crucial for optimizing patient care.

Purpose of the Study:

  • To evaluate the real-world efficacy of CDK4/6 inhibitors (CDKis) in breast cancer patients outside of clinical trials.
  • To identify prognostic and predictive markers associated with treatment response and failure.

Main Methods:

  • A single-center retrospective study analyzed data from November 2016 to May 2020.
  • Progression-free survival (PFS), time-to-treatment failure (TTF), and treatment benefit were assessed.
  • Kaplan-Meier and multivariate regression analyses were employed to identify significant predictors.

Main Results:

  • Of 86 patients, 67.4% experienced treatment failure, with 46.5% due to progression. Median PFS was 12 months and TTF was 8.5 months.
  • 66.3% and 48.8% of patients achieved short-term and prolonged treatment benefit, respectively.
  • Progesterone receptor expression, multiple metastatic sites, hepatic metastasis, adverse events, and diabetes were significant predictors for PFS and TTF. Treatment modifications predicted benefit.

Conclusions:

  • Tailored treatment strategies are essential for optimizing outcomes in real-world breast cancer management.
  • Progesterone receptor expression, metastatic burden, and therapeutic adjustments are key factors in patient response to CDK inhibitors.
  • Further research into personalized treatment approaches is warranted.